William Blair Issues Optimistic Forecast for Incyte Earnings

Incyte Co. (NASDAQ:INCY) – Analysts at William Blair increased their FY2025 earnings per share (EPS) estimates for Incyte in a report released on Tuesday, March 18th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will earn $4.21 per share for the year, up from their prior forecast of $4.20. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $4.86 per share.

Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%.

Several other research firms have also weighed in on INCY. StockNews.com lowered Incyte from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Wells Fargo & Company upped their target price on Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. Royal Bank of Canada lowered their target price on Incyte from $70.00 to $68.00 and set a “sector perform” rating on the stock in a report on Tuesday, February 11th. Stifel Nicolaus upped their target price on Incyte from $75.00 to $77.00 and gave the company a “hold” rating in a report on Monday, February 10th. Finally, JMP Securities reissued a “market perform” rating on shares of Incyte in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $75.13.

Incyte Trading Up 0.4 %

Shares of INCY stock opened at $60.58 on Wednesday. The business’s fifty day moving average price is $70.78 and its 200 day moving average price is $70.13. Incyte has a 1-year low of $50.35 and a 1-year high of $83.95. The firm has a market capitalization of $11.72 billion, a PE ratio of 224.38, a P/E/G ratio of 0.41 and a beta of 0.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94.

Insider Buying and Selling

In related news, EVP Barry P. Flannelly sold 19,807 shares of the stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the transaction, the executive vice president now directly owns 33,567 shares in the company, valued at approximately $2,272,150.23. This represents a 37.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Sheila A. Denton sold 14,069 shares of the firm’s stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total value of $1,042,090.83. Following the completion of the transaction, the executive vice president now owns 25,848 shares in the company, valued at approximately $1,914,561.36. This trade represents a 35.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,827 shares of company stock worth $3,322,618. 17.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Incyte

Large investors have recently modified their holdings of the company. Quintet Private Bank Europe S.A. purchased a new position in shares of Incyte in the 4th quarter worth about $26,000. Global X Japan Co. Ltd. raised its holdings in shares of Incyte by 144.7% in the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 230 shares during the period. R Squared Ltd purchased a new position in shares of Incyte in the 4th quarter worth about $30,000. Brooklyn Investment Group purchased a new position in shares of Incyte in the 3rd quarter worth about $30,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Incyte in the 3rd quarter worth about $33,000. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.